Date: 2015-07-16
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Cell
Company: Visterra (USA - MA)
Product: VIS513
Action
mechanism: monoclonal antibody. VIS513 is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. This antibody is targeting a conserved region on dengue virus domain III of the E protein that is present across all dengue virus serotypes. In preclinical studies, VIS513 binds and potently neutralizes all four serotypes of dengue virus and demonstrates protection of animals challenged with a lethal dose of dengue virus. The company’s preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. Visterra is currently developing VIS513 as a single administration treatment for dengue virus infection in collaboration with Singapore’s Agency for Science, Technology and Research (A*STAR).
Disease: dengue fever
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On July 16, 2015, Visterra, a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, announced that new preclinical results with VIS513, Visterra’s novel monoclonal antibody in development for the treatment of dengue, were published online on July 16, 2015 in the journal Cell (Robinson et al., 2015, Cell 162, 1–12, doi: 10.1016/j.cell.2015.06.057). In the paper titled “Structure-Guided Design of an Anti-Dengue Antibody Directed to a Non-Immunodominant Epitope,” Visterra scientists and scientists at the Massachusetts Institute of Technology (MIT), Duke-National University of Singapore (Duke-NUS), the Singapore-MIT Alliance for Research and Technology (SMART) Center and Nanyang Technological University (NTU) detail preclinical data demonstrating that VIS513 binds and potently neutralizes all four serotypes of dengue virus and protects mice challenged with a lethal dose of dengue virus. These data support the continued development of VIS513 as a single administration treatment for dengue virus infection.
